TAK - Chinese regulators approve Takeda's post-transplant CMV treatment
2023-12-21 16:15:19 ET
More on Takeda Pharmaceutical
- Takeda Pharmaceutical Company Limited (TAK) Q2 2023 Earnings Call Transcript
- Takeda: Why I'm Staying Bearish On This Generic Drug Dividend Play
- Seagen lymphoma drug shows 100% progression free survival in Phase 2 trial
- Takeda wins FDA nod for colorectal cancer therapy
- Seeking Alpha’s Quant Rating on Takeda Pharmaceutical
For further details see:
Chinese regulators approve Takeda's post-transplant CMV treatment